Pipeline

Based on our proprietary platform technology, we are building a strong pipeline of SMNH compounds with a wide range of applications. Our most advanced product candidate, SB 9200 for Hepatitis B and C is currently undergoing final IND enabling GLP toxicology studies with the goal of starting Ph. I clinical trails in 2012.  Behind SB 9200 are drug discovery programs in RSV, COPD, and Broad Spectrum Antiviral.

About Hepatitis

Over 350 million people are chronically infected with HBV virus worldwide. The HBV virus is a DNA virus which incorporates into the hepatocyte DNA. Read More >>

Approximately 170 million people worldwide and 4 million in the United States are infected with HCV. HCV infection is one of the most significant public health threats facing Americans.
Read More >>